The treatment of infections caused by multidrug-resistant Gram-negative bacteria has become increasingly complex, particularly when organisms produce metallo-beta-lactamases (MBLs) such as New Delhi metallo-beta-lactamase (NDM).
Two therapeutic strategies that have received attention in this setting are aztreonam-avibactam and the combination of ceftazidime-avibactam plus aztreonam.
Although both approaches involve aztreonam and an avibactam-containing regimen, they are not the same treatment strategy. They differ in formulation, administration, pharmacokinetic and pharmacodynamic considerations, susceptibility testing, clinical evidence and practical complexity.
The distinction has become particularly relevant as aztreonam-avibactam has entered the clinical treatment landscape and current guidance discusses ceftazidime-avibactam plus aztreonam as an alternative strategy when aztreonam-avibactam is unavailable. 4
This article compares the two approaches while highlighting the limitations of currently available comparative evidence.
What Is the Difference Between Aztreonam-Avibactam and Ceftazidime-Avibactam Plus Aztreonam?
The fundamental difference is how the drugs are combined and administered.
Aztreonam-Avibactam
Aztreonam-avibactam is a fixed combination of aztreonam and avibactam.
The two components are therefore administered as a defined combination designed to provide simultaneous exposure.
Ceftazidime-Avibactam Plus Aztreonam
This is a combination strategy involving separate medicines.
Ceftazidime-avibactam is administered alongside aztreonam rather than using a single fixed aztreonam-avibactam combination.
The strategy was developed around the complementary activity of the individual components against organisms carrying certain resistance mechanisms.
The two approaches therefore share a conceptual foundation but differ substantially in their formulation and administration.
Why Are Both Strategies Discussed for Resistant Gram-Negative Infections?
Metallo-beta-lactamase-producing organisms can present a particular therapeutic challenge.
NDM and other MBLs can hydrolyze many beta-lactam antibiotics.
Aztreonam has an important characteristic in this setting because it is relatively stable to hydrolysis by MBLs.
However, an MBL-producing organism may also produce other beta-lactamases, including serine beta-lactamases such as ESBLs or AmpC enzymes.
Avibactam can inhibit several clinically important serine beta-lactamases, but it does not directly inhibit MBLs such as NDM.
This creates the rationale for combining aztreonam with avibactam-containing strategies.
The clinical question is therefore not simply whether aztreonam or avibactam is active individually. Instead, it involves how the two activities are delivered and maintained against organisms carrying multiple resistance mechanisms.
How Does Aztreonam-Avibactam Work?
Aztreonam-avibactam combines two complementary activities.
Aztreonam
Aztreonam is a monobactam beta-lactam antibiotic that inhibits bacterial cell-wall synthesis by interacting with susceptible penicillin-binding proteins.
Its relative stability to MBL-mediated hydrolysis makes it particularly relevant when organisms produce enzymes such as NDM.
Avibactam
Avibactam is a beta-lactamase inhibitor that inhibits several serine beta-lactamases.
Importantly, avibactam does not directly inhibit metallo-beta-lactamases.
Its role is therefore complementary: it can help protect aztreonam from susceptible serine beta-lactamases that may coexist with an MBL.
The Combined Effect
The combination can therefore be understood as:
MBL such as NDM → does not efficiently hydrolyze aztreonam
while:
Avibactam → inhibits relevant serine beta-lactamases
This complementary mechanism forms the scientific basis for aztreonam-avibactam against selected resistant Gram-negative organisms.
How Does Ceftazidime-Avibactam Plus Aztreonam Differ?
The ceftazidime-avibactam plus aztreonam strategy uses the same broad principle of combining aztreonam with avibactam activity, but the drugs are delivered as separate components.
Ceftazidime-avibactam contributes:
- ceftazidime antibacterial activity; and
- avibactam beta-lactamase inhibition.
Aztreonam contributes:
- beta-lactam antibacterial activity;
- relative stability to metallo-beta-lactamases.
The combination is therefore intended to provide complementary activity against organisms with multiple beta-lactamase mechanisms.
However, because the medicines are administered separately, the pharmacokinetic and administration considerations are different from those of a fixed aztreonam-avibactam combination.
Fixed Combination vs Separate Drug Strategy
One of the most important distinctions is formulation.
| Characteristic | Aztreonam-Avibactam | Ceftazidime-Avibactam + Aztreonam |
|---|---|---|
| Basic structure | Fixed combination | Separate drugs |
| Aztreonam | Included directly | Administered separately |
| Avibactam | Included directly | Delivered through ceftazidime-avibactam |
| Co-exposure | Designed as a fixed combination | Requires coordinated administration |
| Administration | Combination product | Multiple agents |
| PK/PD considerations | Fixed co-exposure | Coordination between separate therapies |
| Susceptibility considerations | Dedicated testing framework | Combination strategy involves separate agents |
| Evidence base | Clinical development programs including REVISIT and ASSEMBLE | Historical and observational experience |
| Direct comparative trials | Limited | Limited |
The 2026 comparison literature specifically identifies fixed and predictable co-exposure as an important distinction, while also discussing potential pharmacokinetic asynchrony when separate drugs are used. 4
What Is Pharmacokinetic Asynchrony?
Pharmacokinetic asynchrony refers broadly to differences in how separately administered drugs are absorbed, distributed, metabolized and eliminated over time.
For a combination strategy involving separate medicines, maintaining appropriate exposure of each component at the relevant site and time can be more complex.
A fixed aztreonam-avibactam combination is designed to provide the two components together.
This does not automatically mean that one strategy is clinically superior in every situation. Rather, it represents a pharmacologic and formulation difference that is relevant when comparing the two approaches.
The 2026 scientific comparison specifically highlights this issue as an area of interest when considering aztreonam-avibactam versus ceftazidime-avibactam plus aztreonam. 4
Does One Strategy Have Better Clinical Evidence?
This question requires caution.
There is no large direct head-to-head clinical trial establishing that aztreonam-avibactam is universally superior to ceftazidime-avibactam plus aztreonam.
The available evidence comes from different types of studies and clinical experiences.
Aztreonam-avibactam has been evaluated in clinical development programs including REVISIT and ASSEMBLE, while ceftazidime-avibactam plus aztreonam has been supported by observational and historical clinical evidence.
Therefore, the evidence should not be interpreted as though both strategies have been evaluated under identical trial conditions.
The 2026 comparison literature specifically emphasizes the lack of direct comparative clinical trials. 4
What Does Current Clinical Guidance Say?
The comparison is also relevant because current antimicrobial-resistance guidance recognizes both strategies in the treatment landscape.
The 2026 IDSA guidance discusses aztreonam-avibactam among preferred options for NDM-producing Enterobacterales and identifies ceftazidime-avibactam plus aztreonam as an alternative when aztreonam-avibactam is unavailable. 4
This does not mean that the two regimens are interchangeable in every patient.
Clinical decisions should consider:
- the organism;
- susceptibility results;
- infection site;
- severity of infection;
- patient-specific factors;
- availability of therapy;
- current local guidance; and
- applicable prescribing information.
How Does Susceptibility Testing Differ?
Susceptibility testing is important for resistant Gram-negative infections because resistance mechanisms can occur together.
For aztreonam-avibactam, laboratories can use a dedicated susceptibility-testing framework where applicable.
The separate ceftazidime-avibactam plus aztreonam strategy creates a more complicated microbiological question because the activity of the individual agents and the combination must be interpreted appropriately.
The purpose of susceptibility testing is not simply to identify an MBL.
An isolate may produce NDM while simultaneously carrying:
- ESBLs;
- AmpC enzymes;
- porin alterations;
- efflux mechanisms; or
- other resistance determinants.
Therefore, laboratory results should be interpreted using current standards and breakpoint criteria.
A detailed discussion of MICs and testing methodology is available in the AIONIOS article on aztreonam-avibactam susceptibility testing.
Is Aztreonam-Avibactam the Same as Ceftazidime-Avibactam Plus Aztreonam?
No.
Although both strategies involve aztreonam and avibactam activity, their formulation and administration are different.
Aztreonam-avibactam is a fixed combination.
Ceftazidime-avibactam plus aztreonam consists of separate medicines administered together as a treatment strategy.
This difference affects:
- drug exposure;
- administration;
- PK/PD considerations;
- laboratory interpretation;
- treatment logistics; and
- the way clinical evidence should be interpreted.
Which Strategy Is Easier to Administer?
From a formulation perspective, a fixed combination can simplify the number of antimicrobial products involved.
Aztreonam-avibactam provides the two relevant components within one combination product.
By comparison, ceftazidime-avibactam plus aztreonam requires separate administration of the products.
However, administration decisions should always follow the applicable prescribing information and institutional protocols.
The practical difference should not be interpreted as a clinical-outcome claim.
What About PK/PD Considerations?
Pharmacokinetic and pharmacodynamic principles are particularly relevant when two antimicrobial components are being used to overcome complementary resistance mechanisms.
For a fixed aztreonam-avibactam combination, the components are formulated to provide coordinated exposure.
For ceftazidime-avibactam plus aztreonam, exposure to the separate drugs depends on their individual pharmacokinetic properties and administration schedules.
The 2026 comparison literature identifies fixed co-exposure, PK/PD coordination and potential PK asynchrony as important areas of distinction. 4
However, these pharmacologic differences should not be presented as proof of superior clinical outcomes in the absence of appropriate comparative trials.
What Are the Main Limitations of the Comparison?
Several limitations should be kept in mind.
Lack of Large Head-to-Head Trials
The two strategies have not been extensively compared in large randomized head-to-head trials.
Different Evidence Sources
The clinical evidence supporting each approach comes from different studies and clinical settings.
Different Patient Populations
Patients enrolled in clinical trials may differ in:
- infection type;
- resistance phenotype;
- disease severity;
- comorbidities; and
- previous antimicrobial exposure.
Evolving Microbiology
Resistance mechanisms continue to evolve.
The presence of NDM does not fully describe an organism’s resistance profile.
Regulatory Differences
Product approvals and indications can differ by country or region.
Therefore, healthcare professionals should consult the relevant local prescribing information rather than transferring regulatory claims from one product or jurisdiction to another.
Aztreonam-Avibactam vs Ceftazidime-Avibactam Plus Aztreonam: Key Differences at a Glance
| Factor | Aztreonam-Avibactam | Ceftazidime-Avibactam + Aztreonam |
|---|---|---|
| Formulation | Fixed combination | Separate medicines |
| Components | Aztreonam + avibactam | Ceftazidime + avibactam + aztreonam |
| MBL rationale | Aztreonam component provides MBL-stable activity | Aztreonam provides MBL-stable activity |
| Avibactam role | Inhibits susceptible serine beta-lactamases | Inhibits susceptible serine beta-lactamases |
| Direct NDM inhibition | No | No |
| Co-exposure | Fixed combination | Requires coordinated administration |
| PK/PD | Designed for coordinated exposure | Separate pharmacokinetic profiles |
| Administration complexity | Combination product | Multiple antimicrobial products |
| Clinical evidence | REVISIT, ASSEMBLE and other evidence | Observational/historical evidence |
| Direct head-to-head evidence | Limited | Limited |
| Clinical selection | Based on current guidance, susceptibility and patient factors | Same principle |
Where Does Meblanios Fit Into the Aztreonam-Avibactam Landscape?
Meblanios is an AIONIOS Pharma product associated with the aztreonam + avibactam injectable combination.
The comparison discussed in this article is primarily about the generic treatment strategies rather than making product-specific regulatory or clinical-evidence claims.
Therefore, evidence concerning EMBLAVEO or other approved products should not automatically be presented as evidence for Meblanios unless supported by applicable Meblanios documentation.
For product-specific information, healthcare professionals can refer to the dedicated Meblanios product page.
Meblanios Aztreonam + Avibactam Injection
Frequently Asked Questions
What is the difference between aztreonam-avibactam and ceftazidime-avibactam plus aztreonam?
Aztreonam-avibactam is a fixed combination of aztreonam and avibactam. Ceftazidime-avibactam plus aztreonam uses separate medicines administered as a combination strategy.
Is aztreonam-avibactam used for NDM-producing bacteria?
Aztreonam-avibactam has an important role in the treatment landscape for selected infections caused by NDM-producing Enterobacterales, subject to susceptibility, clinical circumstances and current guidance.
Does avibactam inhibit NDM?
No. Avibactam does not directly inhibit NDM. Its role is to inhibit susceptible serine beta-lactamases that may coexist with NDM.
Is ceftazidime-avibactam plus aztreonam an alternative to aztreonam-avibactam?
Current IDSA guidance identifies ceftazidime-avibactam plus aztreonam as an alternative when aztreonam-avibactam is unavailable in relevant clinical circumstances. 4
Is aztreonam-avibactam more effective than ceftazidime-avibactam plus aztreonam?
There is not sufficient direct head-to-head clinical evidence to make a universal superiority claim. The two strategies have different formulation, PK/PD and evidence characteristics.
Why is fixed co-exposure important?
A fixed combination is designed to provide coordinated exposure of aztreonam and avibactam. With separate medicines, exposure depends on the pharmacokinetic properties and administration of each component.
Which treatment should be selected?
Treatment selection should be based on the causative organism, susceptibility results, infection site, severity, patient-specific factors, current clinical guidance and applicable prescribing information.
Conclusion
Aztreonam-avibactam and ceftazidime-avibactam plus aztreonam are related but distinct antimicrobial strategies.
Both approaches use the complementary concept of pairing aztreonam’s activity against susceptible Gram-negative bacteria with avibactam-mediated inhibition of relevant serine beta-lactamases.
The major difference is that aztreonam-avibactam is a fixed combination, whereas ceftazidime-avibactam plus aztreonam involves separate antimicrobial products.
This distinction has implications for drug exposure, PK/PD coordination, administration, susceptibility testing and clinical evidence.
Current clinical guidance has made the comparison increasingly relevant, particularly in the setting of NDM-producing Enterobacterales. However, direct comparative clinical evidence remains limited, so the two strategies should not be presented as universally interchangeable or as one being categorically superior.
For healthcare professionals, the most appropriate approach is to consider the organism’s resistance profile, susceptibility results, infection characteristics, patient factors and current antimicrobial guidance when evaluating treatment options.